Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: "Derma Sciences, Inc." (DSCI) Report Updated: Oct 24, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Derma Sciences, Inc." (DSCI)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Health Care Equipment & Supplies
Competitors: EXAC,BAX,PDEX,CMN

Stock Analysis

Rating: Monthly View

October November December January February March April May June July August September

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

"Derma Sciences, Inc."© quotemedia

Company Profile

Derma Sciences, Inc. operates as a tissue regeneration company in the wound care market. Its Advanced Wound Care segment offers MEDIHONEY dressings for managing non-chronic and hard-to-heal wounds, including chronic ulcers, burns, and post-operative wounds; TCC-EZ system for patients with diabetic foot ulcers; AMNIOEXCEL for tissue repair, reconstruction, and replacement; and AMNIOMATRIX that is used as a wound covering in the treatment of localized tissue defects. This segment also provides XTRASORB dressings, which convert fluid within the dressings to a gel and lock the exudates into the dressings; BIOGUARD dressings for prophylactic use in the prevention of hospital or community acquired infections through wound sites; ALGICELL AG antimicrobial dressings; and occlusive dressings, such as hydrocolloids, foams, hydrogels, alginates, additional silver antimicrobial dressings, cleansers, and DERMAGRAN products. The company’s Traditional Wound Care segment offers gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages, and other compression devices; adhesive bandages and related first aid products; private-label wound care products; wound closure strips, nasal tube fasteners, and catheter fasteners; and general purpose and specialized skin care products. Its Pharmaceutical Wound Care segment develops DSC127, an angiotensin analog that is in Phase III clinical trials for the treatment of diabetic foot ulcers, and preclinical testing for scar reduction. The company sells its products to various health care providers, including wound care centers, extended care facilities, acute care facilities, home health care agencies, physicians’ offices, nursing homes, hospitals, and clinics through direct sales and manufacturers’ representatives, independent distributors, and retail channels in the United States, Canada, and the United Kingdom. Derma Sciences, Inc. was founded in 1984 and is headquartered in Princeton, New Jersey.